In the present study we aimed to analyse AML patients in terms of the presence of FLT3-ITD and/or NPM1 gene mutations, telomere length and genetic variability within catalytic subunit of telomerase (TERT) in younger and old AML patients with respect to the clinical data, including overall survival (OS). This evidence concerns the gene FLT3 and acute myeloid leukemia.